MSLE
Satellos Bioscience Inc. Common Stock
1W: -1.1%
1M: -36.1%
YTD: +0.6%
$6.93
-0.19 (-2.67%)
After Hours: $6.97 (+0.04, +0.58%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$9.2M
52W Range4.524-13.395
Volume48,087
Avg Volume61,735
Beta0.71
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFrancis Gleeson
Employees14
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2024-05-10
Websitesatellos.com
Royal Bank Plaza
Toronto, ON M5J 2J1
CA
Toronto, ON M5J 2J1
CA
1 647 660 1780
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
Recent Insider Trades
No insider trades found